Search Patents
  • 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Patent number: 10039724
    Abstract: The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 7, 2018
    Assignee: GW Research Limited
    Inventors: Colin Stott, Marnie Duncan, Vincenzo Di Marzo, Cristoforo Silvestri, Andrea Martella
  • MICROPARTICLES CONTAINING STABILIZED CBD OIL, AND METHODS FOR THE PRODUCTION THEREOF
    Publication number: 20240066041
    Abstract: Food, beverage and nutritional supplements containing microparticles containing stabilised CBD oil, and methods for the production thereof” Food, beverage and nutritional supplements that containing microparticles are described. The microparticles contain CBD oil stabilized in an acacia or inulin fibre or cyclodextrin matrix. Methods for the production of the compositions comprise making the microparticles by providing an oil-in-water microemulsion comprising CBD oil, water, acacia/inulin fibre and optionally maltodextrin or cyclodextrin, and freeze-drying the microemulsion to remove water and provide a preparation of dried microparticles. The dried microparticles comprise a dispersed phase of stabilized microdroplets of CBD oil disposed in a continuous solid matrix comprising acacia or inulin fibre. The preparation of microcapsules contains less than 10% free CBD oil and exhibit improved pharmacokinetics and bioavailability of CD.
    Type: Application
    Filed: March 28, 2022
    Publication date: February 29, 2024
    Inventor: Sinead Bleiel
  • SYSTEMS AND METHODS FOR DETECTING FRAUD
    Publication number: 20140149304
    Abstract: Certain embodiments of the disclosed technology may include systems and methods for detecting fraud. According to an implementation of the disclosed technology, a method is provided that includes: receiving entity-supplied information including at least a name, a social security number, and a mailing address associated with a request for a payment or a benefit from a government agency; querying one or more public or private databases with the entity-supplied information; receiving a plurality of independent information in response to the querying; determining, based at least in part on a comparison of the entity-supplied information with at least a portion of the plurality of independent information, indicators of fraud; and outputting, for display, zero or more indicators of fraud.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 29, 2014
    Applicant: LexisNexis Risk Solutions FL Inc.
    Inventors: Andrew John Bucholz, Scott M. Straub, Monty Faidley, Johannes Philippus de Villiers Prichard, Jesse CBD Shaw, Dermot O'Mahony, David Yeschek, Jennifer Paganacci, Marlene Thorogood, Mark Loizzo
  • INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS
    Publication number: 20210106637
    Abstract: The present invention is a novel and enhanced co-fermentation product of hemp and Cannabis, in which 1 part shredded or divided hemp stems, leaves and flowers are admixed into a slurry with 2 parts water and the slurry is sterilized prior to inoculation with solid or liquid mycelium culture. After inoculation, fermentation takes place at 66-70 degrees F. for 14-28 days, followed by drying of the fermented admixture at 110-165 degrees F. for 24-48 hours, prior to co-minuting or powdering the dried end product for incorporation in oral dosage forms such as pressed tablets, manufactured capsules or powder or as an ingredient in functional foods. By following these method steps including the initial creation of the 2:1 aqueous:hemp slurry, both hemp and mushroom component conversions occur to an unexpected degree.
    Type: Application
    Filed: May 11, 2020
    Publication date: April 15, 2021
    Applicant: BYO Holdings, LLC
    Inventor: Jordan Seth Rubin
  • SYNTHETIC PEPTIDES CORRESPONDING TO OVERLAPPING NEUTRALIZING DETERMINANTS IN THE CBD1 EPITOPE INDUCE BROADLY NEUTRALIZING ANTIBODIES
    Publication number: 20110217307
    Abstract: The present invention relates to chimeric peptides having a caveolin-1 binding domain of an HIV-1 gp41 (CBD1) peptide or a variant of said CBD1, fused to a T helper epitope. In one aspect, the T epitope is from a peptide selected from the group consisting of a tetanus toxin, an HIV-1 Gag p24 and an HIV-1 Env-gp120. Compositions containing these chimeric peptides and pharmaceutical and immunogenic compositions as well as vaccines comprising these chimeric peptides also are part of the present invention. Methods to induce neutralizing antibodies against HIV-1 activity and uses of the chimeric peptides to treat or to prevent HIV-1 infection are also disclosed.
    Type: Application
    Filed: August 27, 2009
    Publication date: September 8, 2011
    Applicant: Centre National de la Recherche Scientifque (CNRS)
    Inventors: Ara Hovanessian, Bernard Krust
  • COMPOSITIONS OF CANNABIDIOL (CBD), AND/OR POLYPHENOLS, AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN, MUSCLE, NERVE AND INFLAMMATORY DISORDERS, AND BIOLOGICAL FACTORS AND FUNCTIONS IN MAMMALS
    Publication number: 20210145764
    Abstract: Described herein are compositions and methods for the prevention and/or treatment of at least one condition or disorder of a) skin and accessory structures of the skin, b) musculoskeletal system, c) cardiovascular system, d) inflammatory system, e) neurological system, f) cancer, and g) endocrine/metabolic system, and/or for improving the health status of a subject. The composition includes one or more polyphenolic compound, its isomer or analog; and one or more other active ingredient selected from the group consisting of collagen, vitamin C, vitamin E, zinc, grape seed extract, niacinamide, hydroxy acids, hyaluronic acid, and coenzyme Q10. The composition may also or alternatively include cannabidiol (CBD).
    Type: Application
    Filed: November 12, 2020
    Publication date: May 20, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventor: Edwin Douglas LEPHART
  • Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
    Patent number: 8173767
    Abstract: The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: May 8, 2012
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Ara Hovanessian, Jean-Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said
  • Methods of producing CBD/THC oils
    Patent number: 11806645
    Abstract: Methods of producing a CBD/THC oil are disclosed. In some embodiments, the method may include extracting CBD/THC from plant matter using one or more solvents, winterizing the solvent extract, and evaporating the one or more solvents from the winterized extract. The method may additionally include distilling the evaporated extract via a short path distillation apparatus to produce an initial distillate oil, mixing the initial distillate oil with at least one solvent, and running the mixture of initial distillate oil and at least one solvent through a chromatography column to produce an effluent. The method may further include evaporating the at least one solvent from the effluent, distilling the evaporated effluent via a short path distillation apparatus to produce a final distillate oil, and mixing one or more desired terpenes with the final distillate oil.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: November 7, 2023
    Assignee: Cannaceutical Extractions LLC
    Inventor: Matt Yale
  • Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
    Patent number: 7364744
    Abstract: The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 29, 2008
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Ara Hovanessian, Jean-Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said
  • Systems and methods for adaptive CBD estimation in a storage device
    Patent number: 8154818
    Abstract: Various embodiments of the present invention provide systems and methods for adaptive channel bit density estimation. For example, various embodiments of the present invention provide methods for adaptively estimating channel bit density. Such methods include providing a storage medium (178) that includes information corresponding to a process data set, and accessing the process data set from the storage medium (505). A first channel bit density estimate (535) is computed based at least in part on a first portion of the process data set (520-530), and a second channel bit density estimate (535) is calculated based at least in part on the first portion of the process data set, a second portion of the process data set (520-530) and the first channel bit density estimate (535).
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: April 10, 2012
    Assignee: LSI Corporation
    Inventors: George Mathew, Yuan Xing Lee, Hongwei Song, Jefferson E. Singleton
  • 3D OBJECT CONTAINING CBD AND PRINTING OPERATING SYSTEM THEREFOR
    Publication number: 20220242050
    Abstract: The present invention relates to a printing operating system for a 3D object containing CBD, the system providing a printing operating method for a 3D object, whereby CBD-containing food, such as coffee, juice, syrup, sauce, ice cream, yogurt, chocolate, cookies, candy, etc., or CBD-containing products using a fluid, such as candles, soaps, cosmetics, oils, etc., are provided by being printed into various and distinctive shapes catering to consumer preferences, while quantitative control and verification are enabled so that the 3D object contains an amount of CBD which is legally allowed in each country. The system implements a teleportation concept-based drug delivery method enabling contactless remote diagnosis and, at the same time, delivery of drugs such as CBD in an emergency situation such as the prevalence of coronaviruses (such as COVID-19) or various infectious diseases.
    Type: Application
    Filed: June 16, 2020
    Publication date: August 4, 2022
    Inventor: Namsoo KIM
  • Novel synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
    Publication number: 20100247618
    Abstract: The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
    Type: Application
    Filed: March 11, 2008
    Publication date: September 30, 2010
    Inventors: Ara Hovanessian, Jean Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said
  • Extracellular expression of cellulose binding domains (CBD) using Bacillus
    Patent number: 6060274
    Abstract: The present invention relates to Bacillus hosts transformed with a vector comprising a DNA sequence encoding for a cellulose binding domain (CBD) and capable of expressing said sequence, the expressed polypeptide protein consisting essentially of one or more non-catalytic domains; the cellulose binding domain having a molecular weight in the range of from 4 kD to 35 kD and being obtainable from a microorganism or from a plant, preferably from a bacterium or a fungus; the Bacillus host e.g. being one of the species Bacillus subtilis, Bacillus licheniformis, Bacillus megaterium, Bacillus stearothermophilos, and Bacillus amyloliquefaciens; and a Bacillus expression vector carrying an inserted DNA sequence encoding for a cellulose binding domain; and a method for producing a cellulose binding domain polypeptide in a Bacillus host cell.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: May 9, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Mads Eskelund Bjornvad, Martin Schulein, Per Lina Jorgensen
  • PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)
    Publication number: 20220387347
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Application
    Filed: January 14, 2022
    Publication date: December 8, 2022
    Inventors: Benjamin WHALLEY, Claire Williams, Gary Stephens, Thomas Hill
  • Pharmaceutical Composition Comprising the Phytocannabinoids Cannabidivarin (CBDV) and Cannabidiol (CBD)
    Publication number: 20200108027
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Application
    Filed: December 10, 2019
    Publication date: April 9, 2020
    Inventors: Benjamin Whalley, Claire Williams, Gary Stephens, Thomas Hill
  • CANNABIDIOL (CBD) BASED COMPOSITION AND METHOD FOR TREATING PAIN
    Publication number: 20240009207
    Abstract: Compositions and methods for relieving acute pain, muscular pain, neuropathic pain, and the chronic pain by administering an effective amount of an analgesic composition (preferably formulated as a cream, a gel, a lotion, an ointment, or a salve) including at least: (i) one or more cannabis compounds; (ii) histamine dihydrochloride, salicylate, camphor, menthol, primrose oil, capsaicin, or any of the combination thereof; and optionally, four or more compounds acting as at least antimicrobial preservative(s), antioxidant(s), dispersant(s), emollient(s), emulsifier(s), humectant(s), lubricant(s), penetration enhancer(s), skin conditioner(s), skin protectant(s), thickener(s), or any of the combination thereof to an affected area of a subject in need of pain relief. In a preferred embodiment, the optional third category contributes six or more compounds. Relief of acute and chronic pain without significant deleterious side effects is provided thereby.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 11, 2024
    Applicant: India Globalization Capital, Inc.
    Inventors: Ramachandra MUKUNDA, Jagadeesh Sridhara RAO
  • A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)
    Publication number: 20140243405
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Application
    Filed: September 14, 2012
    Publication date: August 28, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Benjamin Whalley, Claire Williams, Gary Stephens
  • INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS
    Publication number: 20210154252
    Abstract: The present invention is a novel and enhanced co-fermentation product of hemp and cannabis, in which 1 part by weight shredded or divided hemp stems, leaves and flowers are admixed into a slurry with at least one part by weight up to two parts by weight water and the slurry is sterilized prior to inoculation with solid or liquid mycelium culture. After inoculation, fermentation takes place at 66-70 degrees F. for 14-28 days, followed by drying of the fermented admixture at 110-165 degrees F. for 24-48 hours, prior to co-minuting or powdering the dried end product for incorporation in oral dosage forms such as pressed tablets, manufactured capsules or powder or as an ingredient in functional foods. By following these method steps including the initial creation of aqueous hemp slurry with the prescribed ratio ranges of water, both hemp and mushroom component conversions occur to an unexpected degree.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 27, 2021
    Applicant: Byo Holdings, LLC
    Inventors: Jordan Seth Rubin, Jordan Seth Rubin
  • Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
    Patent number: 11318109
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: May 3, 2022
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Claire Williams, Gary Stephens, Thomas Hill
  • Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
    Patent number: 10729665
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 4, 2020
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Claire Williams, Gary Stephens, Thomas Hill
Narrow Results

Filter by US Classification